ArticleRheumatology (Oxford, England)2026
Impact of smoking status on Sjögren's disease diagnosis and phenotype: results from a cohort study with matched population controls.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo examine associations between smoking and Sjögren's disease (SjD) diagnosis, compared with non-Sjögren's sicca syndrome (sicca) and population controls, and to explore immunomodulatory effects of smoking on disease phenotype.
methodsAdults referred for suspected SjD to the Optimising Assessment in Sjögren's Syndrome (OASIS) cohort from 2014 until 2023 were classified as SjD or sicca. Smoking status, exposure (pack-years) and passive smoking history were recorded through standardized questionnaires. Associations with diagnosis, clinical and serological parameters, and patient-reported outcomes were analysed using multivariate logistic and linear regression. Smoking patterns were further compared with matched controls from the 2018 UK Annual Population Survey.
resultsA total of 317 SjD patients and 170 sicca controls were included. Of these, 257 SjD met 2016 classification criteria, and were used for primary analyses. Smoking data were available for 85.0% of the cohort. SjD patients were more frequently never smokers than sicca (70.5% vs 53.1%, P = 0.002). In the multivariate analysis, current smoking (odds ratio 0.37, 95% CI 0.15-0.92) was independently associated with lower odds of SjD. Never smokers exhibited higher IgG levels (P = 0.003) and more frequent biological EULAR Sjögren's Disease Activity Index activity (P = 0.038). Smoking exposure correlated with reduced IgG, RF levels and seropositivity, independent of DMARD use. Compared with population controls, sicca, but not SjD, showed higher ever-smoking rates (49.6% vs 39.1%, P = 0.049).
conclusionSmoking was negatively associated with SjD diagnosis compared with sicca, but not population controls. Smoking exposure was linked to lower immunoglobulin and autoantibody levels, suggesting an immunomodulatory effect rather than true disease protection. Findings support a potential metabolically influenced, non-autoimmune, sicca phenotype linked to smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.